advertisement
Abstract #22558 Published in IGR 11-1
Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection-related glaucoma
Robin AL; Suan EP; Sjaarda RN; Callanan DG; Defaller J; Alcon Anecortave Acetate for IOP Research TeamArchives of Ophthalmology 2009; 127: 173-178
OBJECTIVE: To evaluate the intraocular pressure (IOP)-lowering potential of anecortave acetate (AA) in eyes with steroid-related ocular hypertension inadequately controlled with the maximal tolerated or appropriate medical therapy. DESIGN: Uncontrolled case series. METHODS: A total of 8 eyes of 7 subjects with medically uncontrolled IOP following intravitreal or sub-Tenon injections of triamcinolone acetonide were included. All received a 0.8-mL anterior juxtascleral depot of 3% AA solution (24 mg) under topical anesthesia. The IOP was assessed weekly for the first month, then monthly for a minimum of 1 year. RESULTS: The mean baseline IOP was 39.9 mmHg. After 1 week, the mean IOP decreased 12 mmHg (29%; P = .005) and by 1 month, the mean IOP had decreased 14.1 mmHg (34.5%; P = .003) from baseline. Four eyes required surgical intervention despite a decrease in IOP because of markedly elevated initial IOP and the degree of preexisting glaucomatous optic neuropathy. We observed no adverse events. CONCLUSIONS: An anterior juxtascleral depot of AA lowers IOP substantially in some eyes with medically uncontrolled steroid-related ocular hypertension. Further study is warranted to clarify the role of AA in treating this condition as well as other forms of glaucoma.
Dr. A.L. Robin, Bloomberg School of Public Health and Wilmer Institute, Johns Hopkins University, Baltimore, Maryland, USA. arobin@glaucomaexpert.com
Classification:
11.14 Investigational drugs; pharmacological experiments (Part of: 11 Medical treatment)
11.15 Other drugs in relation to glaucoma (Part of: 11 Medical treatment)
